Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 72-83

  Sleijfer, Stefan ^a   Ouali, Monia ^b   van Glabbeke, Martine ^b   Krarup Hansen, Anders ^c   Rodenhuis, Sjoerd ^d   Le Cesne, Axel ^e   Hogendoorn, Pancras C W ^f   Verweij, Jaap ^a   Blay, Jean Yves ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CENTRE LÉON BÉRARD   (France)

Author keywords

Ifosfamide based chemotherapy; Prognostic and predictive factors; Soft tissue sarcoma

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; BONE METASTASIS; CHEMOTHERAPY; CONTROLLED STUDY; FACTORIAL ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENDER; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; UNIVARIATE ANALYSIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 71049122368     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.022     Document Type: Article

References (24)

1. Hogendoorn P.C., Collin F., Daugaard S., et al. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 40 (2004) 1644-1654
2. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: a randomised trial. Lancet 364 (2004) 1127-1134
3. Verweij J., van Oosterom A., Blay J.-Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
4. McArthur G.A., Demetri G.D., Van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23 (2005) 866-873
5. Sleijfer S., Seynaeve C., and Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 10 (2005) 833-841
6. Tascilar M., Loos W.J., Seynaeve C., et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 12 (2007) 1351-1360
7. Lorigan P., Verweij J., Papai Z., et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 25 (2007) 3144-3150
8. Verma S., Younus J., Stys-Norman D., et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 34 (2008) 339-347
9. Van Glabbeke M., Van Oosterom A.T., Oosterhuis J.W., et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 17 (1999) 150-167
10. Mouridsen H.T., Bastholt L., Somers R., et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23 (1987) 1477-1483
11. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone sarcoma Group. J Clin Oncol 13 (1995) 1537-1545
12. Nielsen O.S., Dombernowsky P., Mouridsen H., et al. Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcoma. The experience of the EORTC Soft Tissue and Bone sarcoma Group. Sarcoma 4 (2000) 31-35
13. Verweij J., Lee S.M., Ruka W., et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18 (2000) 2081-2086
14. Van Oosterom A.T., Mouridsen H.T., Nielsen O.S., et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38 (2002) 2397-2406
15. Nielsen O.S., Judson I., Van Hoesel Q., et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36 (2000) 61-67
16. Schütte J., Mouridsen H.T., Steward W., et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer Clin Oncol 26 (1990) 558-561
17. Le Cesne A., Judson I., Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization of Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18 (2000) 2676-2684
18. Steward W.P., Verweij J., Somers R., et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic soft tissue sarcomas: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone sarcoma Group. J Clin Oncol 11 (1993) 15-21
19. Klimm B., and Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies. Nature Clin Pract Oncol 5 (2008) 316-323
20. Karavasilis V., Seddon B.M., Ashley S., et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112 (2008) 1585-1591
21. Antman K., Crowley J., Balcerak S.P., et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 (1993) 1276-1285
22. Edmonson J.H., Ryan L.M., Blum R.H., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11 (1993) 1269-1275
23. Spurrell E.L., Fisher C., Thomas J.M., and Judson I.R. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 16 (2005) 437-444
24. Jones R.L., Fisher C., Al-Muderis O., and Judson I.R. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41 (2003) 2853-2860